Primary outcomeMean· 1 year
VEGF Protein and mRNA Levels
| Group | Value (pg/ml) | Spread |
|---|---|---|
| Antagonist-hCG Levels of VEGF | 1395 | 284 |
| Antagonist-aGnRH Levels of VEGF | 1069 | 354 |
| Long Protocol- hCG | 1666 | 55 |
Trial · Observational
CompletedPhase not statedResults postedRegistry dataDifferential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
NCTNCT00848185 (opens ClinicalTrials.gov in a new tab)Other idIVIMAD-MC-10-2008-01
This trial does not test a peptide that PepBank tracks.
- Names Triptorelin (Trelstar, Decapeptyl), does not test it. It appears in the summary.
Overview
- Status
- Completed
- Phase
- Phase not stated
- Enrollment
- 96 participants (actual)
- Sponsor
- IVI Madrid · Other
- Design
- Not stated
- Countries
- Not stated
- Start
- Jun 2008
- Primary completion
- Feb 2009
- Completion
- Mar 2009
- First posted
- 20 Feb 2009 (estimated)
- Last update posted
- 26 Jun 2018
- Conditions
- Vascular Endothelial Growth Factor Overexpression
Timeline
1 trial · 1 completed · 1 with posted results
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
200820092010
- Ph –
Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
NCT00848185Jun 2008 to Mar 2009
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
Introduction OHSS still remains a complication of assisted reproduction treatments. hCG administration to trigger final oocyte maturation will release vascular mediators, being VEGF and other proteins such as VE-Cadherin or Angiopoietin- 2. It has been shown that replacing hCG by GnRH agonists will induce a very short endogenous LH peak, potent enough to induce final oocyte maturation but no OHSS will develop. The investigators examined VEGF, VE-Cadherin and Angiopoietin-2 modulation by hCG as well as GnRH agonists in oocyte donors undergoing controlled ovarian stimulation.
Arms3
Other
Antagonist-hCG for triggering
Protocol with antagonist and hCG to trigger oocyte maturation
Other
Antagonist-aGnRH for triggering
Protocol with antagonist and 0,2 mg triptorelin to trigger oocyte maturation
Other
Long protocol-hCG for triggering
Long Protocol and hCG to trigger oocyte maturation
Primary outcomes1
Outcomes the sponsor listed as primary.
VEGF Protein and mRNA Levels
Time frame · 1 year
Registry description
VEGF concentration in follicular fluid and VEGF mRNA expression in granulosa cells from patients who received either GnRH agonist instead of hCG
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
Primary outcome results
Adverse events, as posted
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| GnRH Antagonist - hCG TriggerGnRH antagonist protocol and hCG trigger | – | 0 / 32 | 0 / 32 |
| GnRH Antagonist Triptorelin TriggerGnRH antagonist protocol and triptorelin trigger | – | 0 / 32 | 0 / 32 |
| Long Protocol - hCG TriggerLong protocol and hCG trigger as control | – | 0 / 32 | 0 / 32 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- Female
- Age
- from 18 Years up to 34 Years
- Healthy volunteers
- Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria:
* Donors
Exclusion Criteria:
* Important diseases
PepBank is a research reference. Talk to a doctor before you use any peptide.